• Home Study Details

  • Home / Learn / Home Study CE / Home Study Details


The Role of Non-Statin Therapies for LDL-C Lowering for Management of ASCVD Risk

Program Type

OnDemand

Credits

1 Contact Hour(s)

Release Date

Wednesday, June 14, 2017

Offline Date:

Monday, June 17, 2019

ACPE Expiration Date

Saturday, December 14, 2019

Target Audience

Nurse, Pharmacist, Pharmacy Technician

Cost

$4.00

  • Overview

    A consensus document detailing the management of dyslipidemia with regard to the use of non-statin therapy was recently released in July 2016. New evidence regarding the use of non-statin therapy (i.e., results from IMPROVE IT and HPS2-THRIVE) has been released and new drugs approved (i.e., the PCSK9 inhibitors) since publication of the 2013 ACC/AHA lipid guideline. This has lead to gaps in the guideline regarding clinical decision making surrounding the use of non-statin drugs. It is imperative to disseminate recommendations of this new decision pathway to healthcare practitioners, so that they can provide evidence-based, patient-centered care as members of an interdisciplinary team.

    Rating


    Handouts

    Slide Document:   16159H01_4pp.pdf
    Slide Document:   16159H01_2pp.pdf

    Financial Support By

    PharmCon, Inc.
  • Nurse

    Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
    Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
    Recognize the role of non-statin pharmacotherapy in dyslipidemia management
    Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia


    Pharmacist

    Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
    Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
    Recognize the role of non-statin pharmacotherapy in dyslipidemia management
    Identify patient-specific pharmacotherapy plans to optimize outcomes for patients with dyslipidemia


    Pharmacy Technician

    Describe the background of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)
    Review recommendations from the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
    Recognize the role of non-statin pharmacotherapy in dyslipidemia management

  • Activity Type

    Knowledge

    Universal Activity Number

    Nurse 0798-0000-16-159-H01-P

    Pharmacist 0798-0000-16-159-H01-P

    Pharmacy Technician 0798-0000-16-159-H01-T

    ACPE PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


HARDWARE REQUIREMENTS
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
 


SOFTWARE REQUIREMENTS
Microsoft Edge
Internet Explorer 8.0 or higher
Google Chrome
Safari
Firefox 3.0.3 or higher


NETWORK REQUIREMENTS
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
 
 

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

 

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyContinuing Education For Healthcare Professionals
Developed By: ITB, Inc.